Evidence map›Paper›PMID 33795488›Full record

Trial reportStroke and vascular neurology2021

Tranexamic acid for acute intracerebral haemorrhage growth based on imaging assessment (TRAIGE): a multicentre, randomised, placebo-controlled trial.

Jingyi Liu, Ximing Nie, Hongqiu Gu, Qi Zhou, Haixin Sun, Ying Tan, Dacheng Liu, Lina Zheng, Jiahui Zhao, Yan Wang and 12 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Stroke and vascular neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 9 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 9 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 1 country.

Jingyi LiuDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0001-7360-0267
Ximing NieDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-8380-4076
Hongqiu GuDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0003-1608-1856
Qi ZhouDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Haixin SunBeijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Ying TanDepartment of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Beijing, China.
Dacheng LiuDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0003-3786-9255
Lina ZhengDepartment of Medicine and Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong.
Jiahui ZhaoDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yan WangDepartment of Neurology, Tangshan People's Hospital, Tangshan, China.
Yibin CaoDepartment of Neurology, Tangshan Gongren Hospital, Tangshan, China.
Haomeng ZhuDepartment of Neurology, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Yunpeng ZhangDepartment of Neurology, Beijing Pinggu Hospital, Beijing, China.
Lijin YiDepartment of Neurology, Liangxiang Hospital of Beijing Fangshan District, Beijing, China.
Yuehua PuDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Miao WenDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Zhonghua YangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Shengjun SunBeijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Wenzhi WangBeijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xingquan ZhaoDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Liping Liu *Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0003-2943-055X
Yongjun Wang *Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China yongjunwang@ncrcnd.org.cn.ORCID 0000-0002-9976-2341
Capital Medical University · CNBeijing Anding Hospital · CNBeijing Luhe Hospital Affiliated to Capital Medical University · CNFirst Affiliated Hospital of Xi'an Jiaotong University · CNPrince of Wales Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStudies show tranexamic acid can reduce the risk of death and early neurological deterioration after intracranial haemorrhage. We aimed to assess whether tranexamic acid reduces haematoma expansion and improves outcome in intracerebral haemorrhage patients susceptible to haemorrhage expansion.

methodsWe did a prospective, double-blind, randomised, placebo-controlled trial at 10 stroke centres in China. Acute supratentorial intracerebral haemorrhage patients were eligible if they had indication of haemorrhage expansion on admission imaging (eg, spot sign, black hole sign or blend sign), and were treatable within 8 hours of symptom onset. Patients were randomly assigned (1:1) to receive either tranexamic acid or a matching placebo. The primary outcome was intracerebral haematoma growth (>33% relative or >6 mL absolute) at 24 hours. Clinical outcomes were assessed at 90 days.

resultsOf the 171 included patients, 124 (72.5%) were male, and the mean age was 55.9±11.6 years. 89 patients received tranexamic acid and 82 received placebo. The primary outcome did not differ significantly between the groups: 36 (40.4%) patients in the tranexamic acid group and 34 (41.5%) patients in the placebo group had intracranial haemorrhage growth (OR 0.96, 95% CI 0.52 to 1.77, p=0.89). The proportion of death was lower in the tranexamic acid treatment group than placebo group (8.1% vs 10.0%), but there were no significant differences in secondary outcomes including absolute intracranial haemorrhage growth, death and dependency.

conclusionsAmong patients susceptible to haemorrhage expansion treated within 8 hours of stroke onset, tranexamic acid did not significantly prevent intracerebral haemorrhage growth. Larger studies are needed to assess safety and efficacy of tranexamic acid in intracerebral haemorrhage patients.

Indexed as

Antifibrinolytic AgentsCerebral HemorrhageTranexamic AcidAdultAgedFemaleHematomaHumansMaleMiddle AgedProspective StudiesAntifibrinolytic AgentsTranexamic AcidCTCT angiographydrughemorrhagestroke

Identifiers

PMID33795488
PMCPMC8258050
OpenAlexW3143388833

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.